Personalis, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PSNL | NEO | CSTL | BLLN | MYGN | BDSX | |
|---|---|---|---|---|---|---|
| Market cap | 1.69B | 2.08B | 1.00B | 4.39B | 401.73M | 271.16M |
| P/E (TTM) | — | — | — | 147.7 | — | — |
| Forward P/E | -16.8 | 47.8 | -34.9 | 62.7 | -7.1 | -116.8 |
| Price/book | 7.1 | 2.6 | 2.1 | 8.1 | 1.3 | 29.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +94.41% | +75.05% | +50.90% | −14.57% | −45.03% | +229.91% |
| Today | −1.25% | −0.92% | −4.82% | −5.12% | −2.55% | −1.23% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All PSNL news ›In Brief Personalis, Tempus, AstraZeneca, Summit, ARUP, More
In Brief This Week: Personalis, Tempus, AstraZeneca, Summit, ARUP, FDA, Agilent, Abbvie, More Genome Web NEW YORK - Investment firm BTIG downgraded Personalis from Buy to Neutral this week based on the expectation that its acquisition by…
Personalis downgraded at BTIG on likely Tempus takeover
Personalis (PSNL) stock slips as BTIG downgrades the cancer test maker, noting that Tempus AI (TEM) will complete its $1.5B M&A deal with the company. Read more here. BTIG on Tuesday downgraded Personalis (PSNL) to Neutral from Buy, noting…
Personalis–Tempus merger waiting period expires
Closing still depends on Personalis stockholder approval and satisfaction or waiver of the other merger conditions. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):…
Personalis: The Wrong Side Of The Merger (NASDAQ:PSNL)
Seeking Alpha - I rate Personalis a Sell at the current share price of $16.57, as the stock already trades above the $16.25 acquisition consideration. - I expect the transaction to close but see limited upside for PSNL shareholders under…
Personalis CMO sells 3,998 shares at $16.22
Personalis, Inc. (PSNL) is a Fremont, California-based genomics company focused on ultrasensitive cancer MRD testing and precision oncology sequencing services. Personalis CMO sells 3,998 shares at $16.22 Personalis’ President and CMO…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
stocktitan.net3
-
seekingalpha.com2
-
genomeweb.com1
-
supplychaindigital.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.